National Institutes of Health (NIH), PHS, DHHS.
Notice of final action under the NIH Guidelines.
Specific proposals to conduct research involving the deliberate transfer of a drug resistance trait to a microorganism that causes disease in humans have been reviewed by the Recombinant DNA Advisory Committee (RAC) and approved by the NIH Director. Approval of these experiments constitutes a Major Action under section III-A-1 of the NIH Guidelines.
This final action is effective September 24, 2007.Start Further Info
FOR FURTHER INFORMATION:
Background documentation and additional information can be obtained from the Office of Biotechnology Activities (OBA), National Institutes of Health, 6705 Rockledge Drive, Suite 750, MSC 7958, Bethesda, Maryland 20892-7958; e-mail at firstname.lastname@example.org, or telephone at 301-496-9838. The NIH/OBA Web site is located at: http://www4.od.nih.gov/oba/.End Further Info End Preamble Start Supplemental Information
This final action allows Dr. Dan Rockey and Dr. Walter Stamm (at Oregon State University and the University of Washington, respectively) to deliberately transfer a gene encoding tetracycline resistance from Chlamydia suis (a swine pathogen) into C. trachomatis (a human pathogen). This approval is specific to Drs. Rockey and Stamm and research with these resistant organisms may only occur under the conditions outlined below. It should be Start Printed Page 61662noted that any work involving the introduction of tetracycline resistance into Chlamydia by other investigators would need to be reviewed by the RAC and specifically approved by the NIH Director.
Background Information and Response to Comments
On May 9, 2007, background on the proposed action, and information on how to submit public comment, was published in the Federal Register (72 FR 26415). On June 20, 2007, the RAC discussed the proposed action at its quarterly public meeting and reviewed the one public comment received. The RAC recommended to the NIH Director that this work be allowed to proceed under Biosafety level (BL) 2+ containment with additional provisions/stipulations. On September 24, 2007, the NIH Director approved the proposed experiments with the following conditions.
(1) Tetracycline resistance will only be introduced into non-ocular strains of C. trachomatis. In conducting this work on tetracycline resistance in C. trachomatis, the following containment standard must be followed:
(2) All research involving the introduction of tetracycline resistance into C. trachomatis must be performed at BL 2 using BL3 practices (referred to as BL2+). The NIH Guidelines articulates requirements for BL2 laboratory facilities and equipment in Appendices G-II-B-3 and G-II-B-4 while BL3 practices are described in Appendices G-II-C-1 and C-2 of the NIH Guidelines. Specifically, the following BL3 practices must be followed:
(a) Access must be restricted to well-trained personnel whose presence is required for the conduct of this work, and
(b) The investigators must use sealed centrifuge rotors and tubes.
(3) In addition, the following procedures and practices must be followed:
(a) Cup sonication must be used rather than probe sonication to separate the infectious form [elementary bodies (EB)] from the metabolically active [reticulate bodies (RB)] form of the bacterium.
(b) If possible, consider using other techniques that do not involve the potential for the generation of aerosols, such as freeze-thaw, to separate EBs from RBs.
(c) No work with the Chlamydia serovars A, B, or C, which cause the ocular disease trachoma, may be conducted in the same laboratory in which tetracycline resistance is being introduced into C. trachomatis serovars that cause genital disease (L, E and G).
(d) An assay to detect the tetracycline resistant genetic element should be developed so that, in the event of a laboratory acquired infection, it will be possible to determine whether the genetically modified strain of Chlamydia is the source of the infection.
(e) The following preventive health surveillance steps should be implemented for any member of the laboratory working with tetracycline resistant C. trachomatis:
(i) In addition to being trained on proper biosafety practices, laboratory workers must be provided education on the possible clinical manifestations of laboratory acquired chlamydial infection.
(ii) Each laboratory must have a detailed, written action plan outlining the specific steps to be taken in the case of a laboratory exposure or infection. This plan should include at a minimum:
(1) Identification of key personnel who would provide diagnostic testing and treatment;
(2) Instructions on managing exposures or infections discovered during off hours (after close of business, holidays, weekends, etc.);
(3) Specific recommendations for managing azithromycin-allergic or sensitive lab workers; and a provision excluding individuals with known macrolide antibiotic allergies from working on these experiments;
(4) Specific recommendations for treatment of infected laboratory personnel who develop side effects while being treated with azithromycin, and
(5) Specific precautions to be taken by infected laboratory workers with respect to protecting close contacts (e.g. family members) from further infection.
(iii) In order to ensure that laboratory members will receive adequate healthcare in the event of infection, an outreach program should be developed to inform healthcare providers who may treat laboratory members about the diagnosis and treatment of tetracycline-resistant Chlamydia. In addition, members of the laboratory should be provided with a medical card that includes at least the following information:
(1) Identification of the personnel responsible for providing diagnosis and treatment;
(2) A CDC telephone number for reporting the infection and obtaining treatment recommendations, and
(3) A twenty-four hour contact number for the principal investigators.
(4) Finally, if tetracycline resistant C. trachomatis is transferred to other laboratories, the investigators working with this tetracycline resistant Chlamydia must follow the identical practices and procedures set forth by the NIH Director. It is the responsibility of Dr. Rockey and Dr. Stamm to ensure and document that the investigators to whom they transfer these strains are apprised of and agree to abide by these requirements. As noted, however, since the NIH Director's approval for the de novo creation of tetracycline resistant strains of non-ocular serovars of C. trachomatis applies only to experiments conducted by Drs. Rockey and Stamm, any work involving the introduction of tetracycline resistance into Chlamydia by other investigators would need to be reviewed by the RAC and specifically approved by the NIH Director.Start Signature
Dated: October 23, 2007.
Amy P. Patterson,
Director, Office of Biotechnology Activities, National Institutes of Health.
[FR Doc. E7-21404 Filed 10-30-07; 8:45 am]
BILLING CODE 4140-01-P